Zhuo M, et al. Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: A cross-sectional registry analysis. Kidney360 2022; 3:455–464. doi: 10.34067/KID.0007862021
KDIGO 2023 CKD Guideline: A Brave New World on the Evaluation, Prognostication, and Management of Kidney Disease. Presented at the European Renal Association (ERA) Congress; June 15–18, 2023; Milan, Italy, and virtual. Accessed February 20, 2024. https://kdigo.org/conferences/era-2023-ckd-guideline-draft-preview/
Zoler ML. FDA approves new drug, sotagliflozin, for heart failure. Medscape. May 26, 2023. https://www.medscape.com/viewarticle/992518
Hoy SM. Bexagliflozin: First approval. Drugs 2023; 83:447–453. doi: 10.1007/s40265-023-01848-x
New diabetes med, Brenzavvy, available through Mark Cuban's online pharmacy. Formulary Watch. July 13, 2023. https://www.formularywatch.com/view/new-diabetes-med-brenzavvy-available-through-mark-cuban-s-online-pharmacy
Brittain B. AstraZeneca wins trial over Zydus’ proposed generic of diabetes drug. Reuters. October 15, 2021. https://www.reuters.com/legal/transactional/astrazeneca-wins-trial-over-zydus-proposed-generic-diabetes-drug-2021-10-15/
Prasco's generic is the brand. Prasco Laboratories. Accessed February 8, 2024. https://prasco.com/what-we-do/authorized-generics.html